健择加泰索帝每周给药治疗晚期非小细胞肺癌的临床研究

Weekly administration of gemcitabine and docetaxel combinations in the treatment of advanced non-small cell lung cancer

目的 观察健择联合泰索帝每周给药治疗晚期非小细胞肺癌的疗效 ,以及两药联合的不良反应。方法 2 6例经病理学或细胞学确诊的晚期NSCLC患者 (初治或复治 )接受健择 80 0～ 12 0 0mg/m2 联合泰索帝 3 5mg/m2 第 1、8、15天静脉滴注 ,每 4周重复。 2周期以上可评价疗效 (包括有效率和中位生存时间 )及不良反应。结果 全组CR 1例 ,PR 6例 ,总有效率为 2 7%。其中 11例初治患者中 5例有效 ,有效率为45 %。中位生存时间 9.5个月 ,1年生存为 3 8% ( 10 / 2 6)。主要不良反应为粒细胞减少及血小板减少 ,有 1例因过敏性休克死亡。结论 健择联合泰索帝每周给药治疗晚期非小细胞肺癌疗效与泰索帝三周及四周方案相似 ,不良反应发生率明显降低 。

Objective To evaluate the efficacy and side effects of weekly administration of gemcitabine combined with docetaxel in the treatment of advanced non small cell lung cancer. Methods Twenty six patients with advanced non small cell lung cancer, with or without prior chemotherapy, were entered into this study. Gemcitabine and docetaxel were administrated weekly for 3 consecutive weeks, followed by 1 week rest. Gemcitabine was given as 800 1 200 mg/m 2 by intravenous infusion on days 1, 8, 15; while docetaxel was 35 mg/m 2 intravenously on the same days as gemcitabine. The efficacy including response rate and median survival duration and toxicity were observed. Results Of the 26 patients, one achieved complete response (CR), and 6 achieved partial response (PR), with an overall response rate of 27%. The median survival duration was 9.5 months and 1 year survival rate was 38% (10/26). The main toxicities were neutropenia and thrombocytopenia. One patient died from allergic shock. Conclusion The combination of docetaxel and gemcitabine is effective and well tolerated in the treatment of advanced NSCLC.